CA2842034C - Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells - Google Patents
Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells Download PDFInfo
- Publication number
- CA2842034C CA2842034C CA2842034A CA2842034A CA2842034C CA 2842034 C CA2842034 C CA 2842034C CA 2842034 A CA2842034 A CA 2842034A CA 2842034 A CA2842034 A CA 2842034A CA 2842034 C CA2842034 C CA 2842034C
- Authority
- CA
- Canada
- Prior art keywords
- inflammasome
- cell
- rpe
- myd88
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007850 degeneration Effects 0.000 title claims description 126
- 239000003112 inhibitor Substances 0.000 title description 129
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 109
- 108090000426 Caspase-1 Proteins 0.000 claims abstract description 79
- 102100035904 Caspase-1 Human genes 0.000 claims abstract description 77
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 71
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims abstract description 66
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract description 65
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 claims abstract description 55
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 claims abstract description 54
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 50
- 230000014509 gene expression Effects 0.000 claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims description 234
- 108010034143 Inflammasomes Proteins 0.000 claims description 76
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 66
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 45
- 239000007924 injection Substances 0.000 claims description 40
- 238000002347 injection Methods 0.000 claims description 40
- 229940122390 Inflammasome inhibitor Drugs 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims description 26
- 208000002780 macular degeneration Diseases 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 230000001684 chronic effect Effects 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 9
- 210000004127 vitreous body Anatomy 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002207 retinal effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 210000003986 cell retinal photoreceptor Anatomy 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 206010048396 Bone marrow transplant rejection Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 210000000981 epithelium Anatomy 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 108091008098 AIM2 inflammasome Proteins 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 206010003267 Arthritis reactive Diseases 0.000 claims description 3
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 3
- 206010069657 Burkholderia cepacia complex infection Diseases 0.000 claims description 3
- 201000003274 CINCA syndrome Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 3
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 3
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 claims description 3
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 claims description 3
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 3
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 claims description 3
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 208000001676 Polyomavirus Infections Diseases 0.000 claims description 3
- 206010063897 Renal ischaemia Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 210000002159 anterior chamber Anatomy 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000007675 cardiac surgery Methods 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims description 3
- 244000000013 helminth Species 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 210000003786 sclera Anatomy 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000037978 tubular injury Diseases 0.000 claims description 3
- 230000010024 tubular injury Effects 0.000 claims description 3
- 230000005747 tumor angiogenesis Effects 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 abstract description 23
- 125000003729 nucleotide group Chemical group 0.000 abstract description 22
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 abstract description 5
- 108010059278 Pyrin Proteins 0.000 abstract description 2
- 102000005583 Pyrin Human genes 0.000 abstract description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 201
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 159
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 158
- 241000699670 Mus sp. Species 0.000 description 114
- 238000000034 method Methods 0.000 description 92
- 102000003810 Interleukin-18 Human genes 0.000 description 87
- 108090000171 Interleukin-18 Proteins 0.000 description 87
- 108090000765 processed proteins & peptides Proteins 0.000 description 82
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 60
- 108020004459 Small interfering RNA Proteins 0.000 description 59
- 230000004913 activation Effects 0.000 description 53
- 239000004055 small Interfering RNA Substances 0.000 description 50
- 229920001184 polypeptide Polymers 0.000 description 49
- 102000004196 processed proteins & peptides Human genes 0.000 description 49
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 48
- 239000000203 mixture Substances 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 43
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 39
- 108010022109 Voltage-Dependent Anion Channel 2 Proteins 0.000 description 37
- 102000012249 Voltage-Dependent Anion Channel 2 Human genes 0.000 description 37
- 241000282414 Homo sapiens Species 0.000 description 36
- 108091034117 Oligonucleotide Proteins 0.000 description 35
- 102000004091 Caspase-8 Human genes 0.000 description 33
- 108090000538 Caspase-8 Proteins 0.000 description 33
- 239000003642 reactive oxygen metabolite Substances 0.000 description 33
- 108010022133 Voltage-Dependent Anion Channel 1 Proteins 0.000 description 32
- 102000012290 Voltage-Dependent Anion Channel 1 Human genes 0.000 description 32
- 239000013615 primer Substances 0.000 description 29
- 230000002441 reversible effect Effects 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 28
- 230000030833 cell death Effects 0.000 description 26
- 239000002158 endotoxin Substances 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 102000002689 Toll-like receptor Human genes 0.000 description 20
- 108020000411 Toll-like receptor Proteins 0.000 description 20
- 238000003776 cleavage reaction Methods 0.000 description 19
- 230000007017 scission Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- -1 NFKB Proteins 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 17
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 231100000135 cytotoxicity Toxicity 0.000 description 16
- 230000003013 cytotoxicity Effects 0.000 description 16
- 238000012216 screening Methods 0.000 description 16
- 230000011664 signaling Effects 0.000 description 16
- 238000001262 western blot Methods 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000002438 mitochondrial effect Effects 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000002679 microRNA Substances 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 12
- 238000000692 Student's t-test Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 102000011727 Caspases Human genes 0.000 description 11
- 108010076667 Caspases Proteins 0.000 description 11
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 101000850658 Homo sapiens Voltage-dependent anion-selective channel protein 3 Proteins 0.000 description 10
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 10
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 10
- 230000006735 deficit Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 9
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 8
- 108700011259 MicroRNAs Proteins 0.000 description 8
- 102000003970 Vinculin Human genes 0.000 description 8
- 108090000384 Vinculin Proteins 0.000 description 8
- 102100033099 Voltage-dependent anion-selective channel protein 3 Human genes 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 210000003470 mitochondria Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 229940100513 Caspase 8 inhibitor Drugs 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 101150053046 MYD88 gene Proteins 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 108020004463 18S ribosomal RNA Proteins 0.000 description 6
- 108091032955 Bacterial small RNA Proteins 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 108010052550 MDL 201053 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- OZLBDYMWFAHSOQ-UHFFFAOYSA-N diphenyliodanium Chemical compound C=1C=CC=CC=1[I+]C1=CC=CC=C1 OZLBDYMWFAHSOQ-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000006010 pyroptosis Effects 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 description 5
- 101710184759 Interleukin-18 receptor 1 Proteins 0.000 description 5
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 4
- 108091023043 Alu Element Proteins 0.000 description 4
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101150023409 Eif2ak2 gene Proteins 0.000 description 4
- 101150089023 FASLG gene Proteins 0.000 description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000004722 NADPH Oxidases Human genes 0.000 description 4
- 108010002998 NADPH Oxidases Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 102000056368 human NLRP3 Human genes 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 3
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 3
- SJDDOCKBXFJEJB-MOKWFATOSA-N Belnacasan Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)C=2C=C(Cl)C(N)=CC=2)C(C)(C)C)CCC1 SJDDOCKBXFJEJB-MOKWFATOSA-N 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000805418 Homo sapiens Voltage-dependent anion-selective channel protein 2 Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150000187 PTGS2 gene Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 101150043341 Socs3 gene Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 3
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000008436 biogenesis Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000006721 cell death pathway Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 102000050702 human PYCARD Human genes 0.000 description 3
- 102000050892 human VDAC2 Human genes 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 102000044166 interleukin-18 binding protein Human genes 0.000 description 3
- 108010070145 interleukin-18 binding protein Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- GVZFUVXPTPGOQT-UHFFFAOYSA-M mitoq Chemical compound CS([O-])(=O)=O.O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C GVZFUVXPTPGOQT-UHFFFAOYSA-M 0.000 description 3
- HPEUEJRPDGMIMY-IFQPEPLCSA-N molybdopterin Chemical compound O([C@H]1N2)[C@H](COP(O)(O)=O)C(S)=C(S)[C@@H]1NC1=C2N=C(N)NC1=O HPEUEJRPDGMIMY-IFQPEPLCSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LPIARALSGDVZEP-SJVNDZIOSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 LPIARALSGDVZEP-SJVNDZIOSA-N 0.000 description 2
- CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 description 2
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 2
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- 101710159080 Aconitate hydratase A Proteins 0.000 description 2
- 101710159078 Aconitate hydratase B Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- 108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 101000805450 Homo sapiens Voltage-dependent anion-selective channel protein 1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 2
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 2
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GNKNIPRNBZCJGO-UHFFFAOYSA-N Malyngamide F acetate Natural products CCCCCCCC(OC)CC=CCCC(=O)NCC(=CCl)C1=CCCC(OC(C)=O)C1=O GNKNIPRNBZCJGO-UHFFFAOYSA-N 0.000 description 2
- 108091028049 Mir-221 microRNA Proteins 0.000 description 2
- 101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 2
- 101100483777 Mus musculus Unc93b1 gene Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
- 241000053208 Porcellio laevis Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 101710105008 RNA-binding protein Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 2
- 108091061750 Signal recognition particle RNA Proteins 0.000 description 2
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- ASXVEBPEZMSPHB-YJBOKZPZSA-N benzyl n-[(2s)-1-[[(2s)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)CF)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ASXVEBPEZMSPHB-YJBOKZPZSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000050854 human VDAC1 Human genes 0.000 description 2
- 102000056699 human VDAC3 Human genes 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108091005434 innate immune receptors Proteins 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- NLZNSSWGRVBWIX-KRCBVYEFSA-N methyl (4s)-5-[[(2s)-1-[[(3s)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2s)-3-(1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoyl]amino]-5-oxopentanoate Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(=O)OC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(=O)OC)C(=O)CF)C(=O)OCC1=CC=CC=C1 NLZNSSWGRVBWIX-KRCBVYEFSA-N 0.000 description 2
- 108091061917 miR-221 stem-loop Proteins 0.000 description 2
- 108091063489 miR-221-1 stem-loop Proteins 0.000 description 2
- 108091055391 miR-221-2 stem-loop Proteins 0.000 description 2
- 108091031076 miR-221-3 stem-loop Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000730 protein immunoprecipitation Methods 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XZFMJVJDSYRWDQ-AWFVSMACSA-N (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid Chemical compound OC(=O)[C@]1(N)CN[C@@H](C(O)=O)C1 XZFMJVJDSYRWDQ-AWFVSMACSA-N 0.000 description 1
- XGWSRLSPWIEMLQ-RQLZCWDZSA-N (2S)-1-[(2S)-3-methyl-1-oxo-2-[[oxo-[(2S,3S)-3-[oxo(propylamino)methyl]-2-oxiranyl]methyl]amino]pentyl]-2-pyrrolidinecarboxylic acid methyl ester Chemical compound CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](C(C)CC)C(=O)N1[C@H](C(=O)OC)CCC1 XGWSRLSPWIEMLQ-RQLZCWDZSA-N 0.000 description 1
- UOUBHJRCKHLGFB-DGJUNBOTSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-chloro-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CCl)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 UOUBHJRCKHLGFB-DGJUNBOTSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100028100 Activating signal cointegrator 1 Human genes 0.000 description 1
- 101710089542 Activating signal cointegrator 1 Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- 101710100501 CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 102000004066 Caspase-12 Human genes 0.000 description 1
- 108090000570 Caspase-12 Proteins 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 101710090338 Caspase-4 Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
- 101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 1
- 101100459282 Homo sapiens MB gene Proteins 0.000 description 1
- 101000962053 Homo sapiens Pyrin Proteins 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 101150047285 Il1r1 gene Proteins 0.000 description 1
- 101710128560 Initiator protein NS1 Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 101710085994 Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 1
- 101710166699 Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
- 101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
- 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
- 108010093442 L 709049 Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 108091028232 Mir-184 Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 1
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
- 101100233098 Mus musculus Ifngr1 gene Proteins 0.000 description 1
- 101100079026 Mus musculus Myd88 gene Proteins 0.000 description 1
- 101100404869 Mus musculus Nlrp3 gene Proteins 0.000 description 1
- 229940123857 NADPH oxidase inhibitor Drugs 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 108010036473 NLR Proteins Proteins 0.000 description 1
- 101710144127 Non-structural protein 1 Proteins 0.000 description 1
- XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 101710181913 Serine proteinase inhibitor 2 Proteins 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YCUVUDODLRLVIC-UHFFFAOYSA-N Sudan black B Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1N=NC(C1=CC=CC=C11)=CC=C1N=NC1=CC=CC=C1 YCUVUDODLRLVIC-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 1
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- MDDIUTVUBYEEEM-UHFFFAOYSA-N azane;pyrrolidine-1-carbodithioic acid Chemical compound N.SC(=S)N1CCCC1 MDDIUTVUBYEEEM-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229950010527 belnacasan Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010378 bimolecular fluorescence complementation Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 125000003636 chemical group Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003173 enzyme complementation Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 102000043959 human IL18 Human genes 0.000 description 1
- 102000055222 human IL1B Human genes 0.000 description 1
- 102000051001 human MEFV Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010507 innate immune sensing pathway Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940126181 ion channel inhibitor Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 230000005817 liver abnormality Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- PHLCQASLWHYEMX-DEKIMQJDSA-N methyl (4s)-5-[[(2s,3r)-1-[[(3s)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[[(2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoate Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)OCC1=CC=CC=C1 PHLCQASLWHYEMX-DEKIMQJDSA-N 0.000 description 1
- 108091059501 miR-320a stem-loop Proteins 0.000 description 1
- 108091088570 miR-320a-1 stem-loop Proteins 0.000 description 1
- 108091070041 miR-320a-2 stem-loop Proteins 0.000 description 1
- 108091065447 miR-320a-3 stem-loop Proteins 0.000 description 1
- 108091054114 miR-320a-4 stem-loop Proteins 0.000 description 1
- 108091080700 miR-484 stem-loop Proteins 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229950000362 pralnacasan Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000019539 pyogenic bacterial infections due to MyD88 deficiency Diseases 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3205596A CA3205596A1 (en) | 2011-07-18 | 2012-07-16 | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508867P | 2011-07-18 | 2011-07-18 | |
| US61/508,867 | 2011-07-18 | ||
| US201161543038P | 2011-10-04 | 2011-10-04 | |
| US61/543,038 | 2011-10-04 | ||
| PCT/US2012/046928 WO2013012806A2 (en) | 2011-07-18 | 2012-07-16 | Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3205596A Division CA3205596A1 (en) | 2011-07-18 | 2012-07-16 | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2842034A1 CA2842034A1 (en) | 2013-01-24 |
| CA2842034C true CA2842034C (en) | 2023-09-05 |
Family
ID=47558691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2842034A Active CA2842034C (en) | 2011-07-18 | 2012-07-16 | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
| CA3205596A Pending CA3205596A1 (en) | 2011-07-18 | 2012-07-16 | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3205596A Pending CA3205596A1 (en) | 2011-07-18 | 2012-07-16 | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9453226B2 (enExample) |
| EP (2) | EP2734240B1 (enExample) |
| JP (1) | JP6313203B2 (enExample) |
| CN (1) | CN103889461B (enExample) |
| AU (1) | AU2012284223B2 (enExample) |
| CA (2) | CA2842034C (enExample) |
| ES (1) | ES2907620T3 (enExample) |
| PT (1) | PT3366302T (enExample) |
| WO (1) | WO2013012806A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138555A2 (en) | 2009-05-26 | 2010-12-02 | University Of Florida Research Foundation, Inc. | Small peptide expression system in mammalian cells |
| WO2012053741A2 (ko) | 2010-10-22 | 2012-04-26 | 성균관대학교산학협력단 | Rna 간섭을 유도하는 핵산 분자 및 그 용도 |
| US9707235B1 (en) * | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| US20130297023A1 (en) * | 2012-05-07 | 2013-11-07 | Hee-Jeong Im Sampen | Methods and Devices For Treating Intervertebral Disc Disease |
| KR101567576B1 (ko) | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도 |
| WO2014039696A2 (en) | 2012-09-05 | 2014-03-13 | Cold Spring Harbor Laboratory | Transposable elements, tdp-43, and neurodegenerative disorders |
| WO2014164703A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
| US9326983B2 (en) | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
| WO2015095609A1 (en) * | 2013-12-19 | 2015-06-25 | The J. David Gladstone Institute | Inhibition of interferon-gamma-inducible protein 16 (ifi16) |
| WO2015127094A1 (en) | 2014-02-19 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Delivery of nrf2 as therapy for protection against reactive oxygen species |
| WO2015138628A1 (en) * | 2014-03-11 | 2015-09-17 | University Of Florida Research Foundation, Inc. | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic |
| WO2016022914A1 (en) * | 2014-08-08 | 2016-02-11 | Moderna Therapeutics, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
| US11219623B2 (en) | 2015-02-26 | 2022-01-11 | University Of Kentucky Research Foundation | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis |
| ES3010307T3 (en) | 2015-02-26 | 2025-04-02 | Univ Kentucky Res Found | Compositions and methods for treating retinal degradation |
| JP7085712B2 (ja) * | 2015-09-03 | 2022-06-17 | ビー．ジー． ネゲヴ テクノロジーズ アンド アプリケーションズ リミテッド、アット ベン－グリオン ユニヴァーシティ | Ｖｄａｃ１由来ペプチドの類似体 |
| US11174484B2 (en) | 2015-11-10 | 2021-11-16 | B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
| JP7027311B2 (ja) * | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| KR102825946B1 (ko) | 2016-02-02 | 2025-06-27 | 올릭스 주식회사 | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 |
| CN109415413A (zh) * | 2016-06-07 | 2019-03-01 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 髓样分化因子88(myd88)的主链环化抑制肽 |
| US11130951B2 (en) * | 2016-06-09 | 2021-09-28 | The General Hospital Corporation | Modulating the cellular stress response |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| US20190185820A1 (en) * | 2016-08-26 | 2019-06-20 | The Regents Of The University Of California | Compositions and Methods for Inhibiting Stem Cell Aging |
| PL3558335T3 (pl) | 2016-12-23 | 2023-08-21 | Casp-Aid Inc. | Inhibicja kaspazy-1 i jej zastosowanie w zapobieganiu i leczeniu schorzeń neurologicznych |
| JP7424728B2 (ja) | 2017-02-10 | 2024-01-30 | オリック パルマセゥティカルズ インコーポレイテッド | Ｒｎａ干渉のための長鎖の二本鎖ｒｎａ |
| GB2561540A (en) | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| JP2020515625A (ja) * | 2017-04-03 | 2020-05-28 | デューク ユニバーシティ | 細胞死およびインターフェロン発現の差次的誘導のための組成物および方法 |
| US20200345756A1 (en) * | 2017-10-10 | 2020-11-05 | University Of Virginia Patent Foundation | Compositions and methods for treating age-related macular degeneration and geographic atrophy |
| WO2020006229A1 (en) * | 2018-06-27 | 2020-01-02 | Children's Medical Center Corporation | Compounds for inhibition of inflammation |
| KR102138256B1 (ko) * | 2018-09-13 | 2020-08-13 | 한국과학기술연구원 | 케스페이즈-1 활성 측정용 프로브, 이를 포함하는 염증성 질환 진단용 조성물 |
| EP3863714A4 (en) * | 2018-10-09 | 2022-07-20 | University of Virginia Patent Foundation | ENDOGENOUS CYTOPLASMATIC ALU-COMPLEMENTARY DNA IN AGE-RELATED MACULAR DEGENERATION |
| CN110305957B (zh) * | 2019-08-22 | 2022-07-29 | 中国水产科学研究院淡水渔业研究中心 | 一种鉴定黄颡鱼脂肪肝程度的试剂盒及其鉴定方法 |
| WO2021041317A1 (en) * | 2019-08-23 | 2021-03-04 | University Of Virginia Patent Foundation | Ddx17 and nlrc4 targeting for inflammatory diseases |
| US20230070129A1 (en) * | 2020-01-06 | 2023-03-09 | Seasun Therapeutics | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
| WO2021163327A1 (en) * | 2020-02-11 | 2021-08-19 | University Of Virginia Patent Foundation | Compositions and methods for treating and/or preventing ocular disorders |
| CN111358950A (zh) * | 2020-03-20 | 2020-07-03 | 厦门大学 | Caspase-1及ASC/Caspase-8作为靶点的应用 |
| EP4192952A1 (en) * | 2020-08-10 | 2023-06-14 | Novartis AG | Treatments for retinal degenerative diseases |
| MX2023005699A (es) | 2020-11-18 | 2023-05-29 | Novartis Ag | Anticuerpos biespecificos para el uso en el tratamiento de inflamasomopatia nlrc4-gof. |
| CN115969844B (zh) * | 2021-12-28 | 2024-04-02 | 首都医科大学附属北京同仁医院 | Nox2特异性抑制剂在制备视网膜变性药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| AU2988200A (en) * | 1999-02-11 | 2000-08-29 | Trustees Of The University Of Pennsylvania, The | Regulation of photoreceptor degeneration |
| GB9930616D0 (en) * | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| US20030186903A1 (en) * | 2001-11-23 | 2003-10-02 | Isis Pharmaceuticals Inc. | Antisense modulation of MyD88 expression |
| WO2003057728A1 (en) * | 2002-01-10 | 2003-07-17 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | A novel splice variant of myd88 and uses thereof |
| EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9549895B2 (en) * | 2004-04-23 | 2017-01-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
| WO2006067091A1 (en) | 2004-12-20 | 2006-06-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Myd88 homodimerization inhibitors |
| US7879992B2 (en) * | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| EP1746167A1 (en) * | 2005-07-20 | 2007-01-24 | Apoxis SA | Method for the identification of compounds susceptible to inhibit inflammation |
| WO2007077042A1 (en) * | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
| WO2008070579A2 (en) | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
| AU2008260572A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | IL- 18 and protein kinase R inhibition for the treatment of COPD |
| US20090227487A1 (en) * | 2008-03-05 | 2009-09-10 | Jeremy Pearl | Methods for the control of macrophage-associated inflammation |
| WO2010017436A2 (en) * | 2008-08-08 | 2010-02-11 | Idera Pharmaceuticals, Inc. | Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides |
| EP2560629B1 (en) * | 2010-04-23 | 2020-06-03 | Massachusetts Eye & Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| WO2011153234A2 (en) | 2010-06-01 | 2011-12-08 | University Of Kentucky Research Foundation | Methods of inhibiting alu rna and therapeutic uses thereof |
| US20120177632A1 (en) * | 2011-01-10 | 2012-07-12 | Shinohara Mari L | Methods of optimizing disease treatment |
-
2012
- 2012-07-16 EP EP12814249.4A patent/EP2734240B1/en active Active
- 2012-07-16 CA CA2842034A patent/CA2842034C/en active Active
- 2012-07-16 EP EP18156266.1A patent/EP3366302B1/en active Active
- 2012-07-16 PT PT181562661T patent/PT3366302T/pt unknown
- 2012-07-16 WO PCT/US2012/046928 patent/WO2013012806A2/en not_active Ceased
- 2012-07-16 AU AU2012284223A patent/AU2012284223B2/en active Active
- 2012-07-16 CA CA3205596A patent/CA3205596A1/en active Pending
- 2012-07-16 CN CN201280045438.0A patent/CN103889461B/zh active Active
- 2012-07-16 JP JP2014521695A patent/JP6313203B2/ja active Active
- 2012-07-16 ES ES18156266T patent/ES2907620T3/es active Active
-
2014
- 2014-01-17 US US14/158,357 patent/US9453226B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2842034A1 (en) | 2013-01-24 |
| CN103889461A (zh) | 2014-06-25 |
| EP2734240A2 (en) | 2014-05-28 |
| CA3205596A1 (en) | 2013-01-24 |
| US20140178309A1 (en) | 2014-06-26 |
| WO2013012806A2 (en) | 2013-01-24 |
| EP2734240B1 (en) | 2018-03-21 |
| WO2013012806A3 (en) | 2013-05-30 |
| ES2907620T3 (es) | 2022-04-25 |
| AU2012284223B2 (en) | 2017-06-22 |
| US9453226B2 (en) | 2016-09-27 |
| EP3366302B1 (en) | 2021-12-08 |
| EP3366302A1 (en) | 2018-08-29 |
| JP6313203B2 (ja) | 2018-04-18 |
| CN103889461B (zh) | 2016-11-09 |
| AU2012284223A1 (en) | 2014-02-06 |
| JP2014528700A (ja) | 2014-10-30 |
| PT3366302T (pt) | 2022-03-07 |
| EP2734240A4 (en) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2842034C (en) | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells | |
| US11730743B2 (en) | Protection of cells from degeneration and treatment of geographic atrophy | |
| Tarallo et al. | DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88 | |
| Kerur et al. | TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy | |
| EP2340040B1 (en) | Modulation of axon degeneration | |
| US12274701B2 (en) | Compositions and methods for treating retinal degradation | |
| Wang et al. | Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice | |
| Yang et al. | White spot syndrome virus infection activates Caspase 1-mediated cell death in crustacean | |
| Ding et al. | Alamandine, a new member of the renin-angiotensin system (RAS), attenuates collagen-induced arthritis in mice via inhibiting cytokine secretion in synovial fibroblasts | |
| Tiffney et al. | Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii | |
| Chan | Macrophage Response to Interleukin-1 Stimulation and the Nature of Cell Surface Interleukin-1 Alpha | |
| Rathkey | Gasdermin D as the Effector of Pyroptotic Cell Death | |
| Latreille | Identification of a novel anti-inflammatory compound that acts via the Nrf2 pathway | |
| KR20200028982A (ko) | 시냅스 기능을 증진시키기 위한 hdac2-sp3 복합체 표적화 | |
| Kasumba | A plant-derived nucleic acid protects mice from respiratory viruses in an IFN-I-dependent and independent manner | |
| Lê-Bury et al. | The unique lipopolysaccharide composition of Salmonella Typhimurium ST313 dampens pyroptosis and inflammasome activation and suppresses host cell death | |
| Lu et al. | Agomir-223 treatment after lung blast injury reduces the inflammatory response by regulating the NLRP3 inflammasome to inhibit M1 macrophage function | |
| Marrero | Investigating Cell Type-Specific Responses to Legionella pneumophila Infection | |
| Suen | Circulating MicroRNAs Trigger Innate Immune Activation in Polytraumatic Injury | |
| Heir | Glial tumour necrosis factor in synaptic scaling and the regulation of immune molecules by neuronal activity | |
| Rodemer | Interactions between the axon tip and its environment in regulating neuronal survival and axon regeneration: roles of the CSPG receptor, PTPσ, and delayed axolemmal resealing. | |
| Bugde | Role of ABCC5 in gemcitabine resistance in pancreatic cancer | |
| Lockett | Coordination of LPS, TNFα and IL-1β signaling by IRAK-1 posttranslational modification | |
| Deplano | Role of P2X7-Mediated Inflammasome Activation in Glomerulonephritis | |
| Ho | Purinergic receptors responsible for ATP-dependent ROS production and activation of inflammasomes in gingival epithelial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |
|
| EEER | Examination request |
Effective date: 20170222 |